ArticleCureus2025
Lung Stereotactic Body Radiotherapy (SBRT) on Metastatic Sarcomas: A Retrospective Study at a Quaternary Center.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction and purposeLung metastases are common in sarcoma patients, often necessitating systemic therapy or local therapies. Stereotactic body radiotherapy (SBRT) offers a targeted approach, achieving low local failure (LF) and delaying systemic therapy. This study evaluates the outcomes of SBRT for sarcoma lung metastases, focusing on LF, systemic therapy-free survival (STFS), and overall survival (OS). METHODS AND MATERIALS: Retrospective study of patients with metastatic pulmonary lesions treated with SBRT between September 2015 and December 2022. STFS was defined as the time from the end of the first RT course to the start of any systemic therapy, if no previous systemic therapy was given or if a pause of at least one month was achieved with RT. STFS was depicted as a Kaplan-Meier curve. LF was analyzed using a competing risks framework. The response assessment was evaluated based on pre- and post-treatment chest CT or PET-CT. Toxicities were classified according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.
resultsA total of 17 patients and 53 lesions were treated in 31 courses of treatment. Median follow-up was 96 months. Median number of lesions treated per treatment course was 2 (range: 1-4). In 94.1% of the treatment courses, the target was the only active site of active disease. In 79.2% of the lesions treated, the biologically effective dose (BED) was equal to or superior to 100Gy with a median BED of treated lesions of 105.6Gy (range: 67.2-180Gy). No SBRT-related toxicities were reported. LF rates at one-, two-, and three-years were 32.0%, 45.3% and 47.2%, respectively. Median STFS was 26 months. STFS rates at one- and two-years were 62% (CI95% 40-95) and 54% (CI95% 33-89), respectively. Median OS was 34 months. OS rates at one- and two-years were both 71% (CI95% 53.3-85.6).
conclusionSBRT is a promising strategy for managing lung metastases in sarcoma, offering acceptable local control (LC) rates and significant systemic therapy-free survival without accrued toxicities. Further research should focus on optimizing dose schedules and patient selection to enhance outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.